Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Other Non-Current Assets (2016 - 2025)

Celldex Therapeutics has reported Other Non-Current Assets over the past 16 years, most recently at $13.4 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $13.4 million for Q4 2025, up 37.05% from a year ago — trailing twelve months through Dec 2025 was $13.4 million (up 37.05% YoY), and the annual figure for FY2025 was $13.4 million, up 37.05%.
  • Other Non-Current Assets for Q4 2025 was $13.4 million at Celldex Therapeutics, up from $9.4 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for CLDX hit a ceiling of $13.4 million in Q4 2025 and a floor of $41000.0 in Q1 2021.
  • Median Other Non-Current Assets over the past 5 years was $107000.0 (2023), compared with a mean of $3.2 million.
  • Peak annual rise in Other Non-Current Assets hit 9628.04% in 2025, while the deepest fall reached 3.93% in 2025.
  • Celldex Therapeutics' Other Non-Current Assets stood at $104000.0 in 2021, then changed by 0.0% to $104000.0 in 2022, then grew by 2.88% to $107000.0 in 2023, then surged by 9009.35% to $9.7 million in 2024, then surged by 37.05% to $13.4 million in 2025.
  • The last three reported values for Other Non-Current Assets were $13.4 million (Q4 2025), $9.4 million (Q3 2025), and $9.3 million (Q2 2025) per Business Quant data.